Walleye Capital’s Adaptive Biotechnologies ADPT Stock Holding History

Walleye Capital’s Portfolio ADPT Stock Details ADPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-95,324	Closed	-$1.55M	–	4323
2025 Q4	$1.55M	Buy	95,324 +5,138	+6%	+$83.9K	﹤0.01%	2071
2025 Q3	$1.35M	Buy	+90,186	New	+$1.1M	0.01%	1862
2025 Q1	–	Sell	-15,732	Closed	-$94.3K	–	4168
2024 Q4	$94.3K	Buy	+15,732	New	+$86.7K	﹤0.01%	4163
2024 Q1	–	Sell	-18,695	Closed	-$91.6K	–	5369
2023 Q4	$91.6K	Buy	+18,695	New	+$85.3K	﹤0.01%	4076
2023 Q1	–	Sell	-22,168	Closed	-$169K	–	3876
2022 Q4	$169K	Buy	+22,168	New	+$172K	﹤0.01%	2142
2021 Q2	–	Sell	-10,462	Closed	-$421	–	1316
2021 Q1	$421	Buy	+10,462	New	+$566K	0.02%	643
2020 Q4	–	Sell	-8,253	Closed	-$401K	–	912
2020 Q3	$401K	Buy	+8,253	New	+$347K	0.04%	438

Other funds holding ADPT

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Walleye Capital's ADPT Position: Q1 2026 in Review

Walleye Capital sold out of Adaptive Biotechnologies (ADPT) in Q1 2026, closing a stake of 95,324 shares — an estimated $1.55M sold.

Walleye Capital first reported a position in ADPT in Q3 2020 and held it in 7 quarters. The position peaked at $1.55M in Q4 2025. 295 funds tracked by Wall St. Rank hold ADPT as of Q1 2026.

Walleye Capital reported no remaining Adaptive Biotechnologies position as of Q1 2026 after selling out during the quarter.
Walleye Capital sold 95,324 Adaptive Biotechnologies shares in Q1 2026, an estimated $1.55M.
Walleye Capital first reported a position in Adaptive Biotechnologies in Q3 2020 and held it in 7 quarters.
Walleye Capital's Adaptive Biotechnologies position peaked at $1.55M in Q4 2025.
295 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q1 2026.

Based on Walleye Capital's 13F filing for Q1 2026, filed 11 May 2026.